Myocardial Damage In Patients With Cerebral Infarction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00306579|
Recruitment Status : Completed
First Posted : March 24, 2006
Last Update Posted : August 8, 2017
For several years "ischemic" electrocardiographic (ECG) changes in the acute phase of ischemic stroke have been reported. Whether these ECG changes reflect true myocardial ischemia remains controversial. So far no study has assessed different markers of myocardial ischemia or necrosis in consecutive patients admitted to hospital with an acute ischemic stroke.
The main purpose of this study is to determine the potential burden of reversible and irreversible myocardial ischemia in patients with an acute ischemic stroke.
Patients and methods
Serial blood samples for measuring troponin T, CK-MB and NT-proBNP are collected in 250 patients with evidence of an acute ischemic stroke admitted to the Department of Neurology at Odense University Hospital. In addition resting 12-lead ECG recordings will be obtained on a daily basis, and a 24-hour ST-segment ambulatory monitoring will be performed once within the first week of hospitalisation. Finally, myocardial perfusion patterns during rest will be evaluated by means of a myocardial perfusion scintigraphy in patients with an elevated troponin T level.
Six months later control measurements of troponin T, CK-MB and NT-proBNP and a 12-lead ECG will be obtained.
The study will contribute with original observations in patients with acute ischemic stroke considering the following issues:
- The prevalence and characteristics of ECG changes suggestive of myocardial ischemia.
- The prevalence of transient ST-segment changes on ambulatory monitoring.
- The prevalence and degree of myocardial necrosis as judged from biochemical markers.
- The prevalence of reversible and irreversible perfusion defects on myocardial scintigraphy.
- The prevalence, size and patterns of NT-proBNP.
- Whether there is a change in ECG and biochemical markers over a 6-month follow-up period.
The results may have clinical implications regarding early and late treatment as well as clinical follow-up of patients recovering from an episode of acute ischemic stroke.
|Condition or disease|
|Study Type :||Observational|
|Enrollment :||250 participants|
|Official Title:||Myocardial Damage In Patients With Cerebral Infarction. Prevalence and Characteristics as Measured by Troponins, Electrocardiographic Changes and Myocardial Perfusion Imaging.|
|Study Start Date :||August 2003|
|Study Completion Date :||May 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00306579
|Principal Investigator:||Jesper K. Jensen, MD||Department of Cardiology, Odense University Hospital|
|Study Director:||Hans Mickley, DMSci||Department of Cardiology, Odense University Hospital|
|Study Chair:||Søren Bak, MD, PhD||Department of Neurology, Odense University Hospital|
|Study Chair:||Poul Flemming H. Carlsen, DMSci||Department of Nuclear Medicine, Odense University Hospital|
|Study Chair:||Søren R. Kristensen, DMSci||Department of Clinical Chemistry, Aalborg Hospital|